CR20210192A - Análogos de proteína tirosina-tirosina y métodos de uso de esta - Google Patents

Análogos de proteína tirosina-tirosina y métodos de uso de esta

Info

Publication number
CR20210192A
CR20210192A CR20210192A CR20210192A CR20210192A CR 20210192 A CR20210192 A CR 20210192A CR 20210192 A CR20210192 A CR 20210192A CR 20210192 A CR20210192 A CR 20210192A CR 20210192 A CR20210192 A CR 20210192A
Authority
CR
Costa Rica
Prior art keywords
tyrosine
analogs
methods
disclosed
same
Prior art date
Application number
CR20210192A
Other languages
English (en)
Inventor
Daniel Anthony Briere
Avinash Muppidi
Daniel Christopher Lopes
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20210192A publication Critical patent/CR20210192A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen análogos de PYY que incluyen modificaciones que aumentan la semivida en comparación con PYY humano, nativo, así como modificaciones adicionales que aumentan la potencia y selectividad para el receptor NPY2. También se describen composiciones farmacéuticas que incluyen uno o más de los análogos de PYY descritos en la presente en un portador aceptable desde el punto de vista farmacéutico. También se describen métodos para elaborar y usar los análogos de PYY, especialmente para tratar la obesidad y las enfermedades y los trastornos relacionados con la obesidad, tales como diabetes mellitus tipo II.
CR20210192A 2018-11-01 2019-10-28 Análogos de proteína tirosina-tirosina y métodos de uso de esta CR20210192A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754244P 2018-11-01 2018-11-01
US201962793544P 2019-01-17 2019-01-17
PCT/US2019/058259 WO2020092191A1 (en) 2018-11-01 2019-10-28 Protein tyrosine-tyrosine analogs and methods of using the same

Publications (1)

Publication Number Publication Date
CR20210192A true CR20210192A (es) 2021-05-18

Family

ID=68582448

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210192A CR20210192A (es) 2018-11-01 2019-10-28 Análogos de proteína tirosina-tirosina y métodos de uso de esta

Country Status (20)

Country Link
US (2) US11155592B2 (es)
EP (1) EP3873924A1 (es)
JP (2) JP7280949B2 (es)
CN (1) CN112888705A (es)
AU (2) AU2019371232B2 (es)
BR (1) BR112021006782A2 (es)
CA (1) CA3118002A1 (es)
CL (1) CL2021001073A1 (es)
CO (1) CO2021005514A2 (es)
CR (1) CR20210192A (es)
DO (1) DOP2021000072A (es)
EC (1) ECSP21030933A (es)
IL (1) IL282177A (es)
MX (1) MX2021004930A (es)
MY (1) MY197530A (es)
PE (1) PE20211466A1 (es)
PH (1) PH12021550964A1 (es)
SG (1) SG11202104161RA (es)
TW (2) TWI749381B (es)
WO (1) WO2020092191A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
CA3185637A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
CN117603364A (zh) * 2022-09-30 2024-02-27 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515533A (ja) 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝障害を治療するためのペプチドｙｙおよびペプチドｙｙアゴニスト
AU2003201998C1 (en) * 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US20070027073A1 (en) 2003-04-08 2007-02-01 Menachem Rubinstein Long-acting derivatives of pyy agonists
CA2723855A1 (en) 2008-05-16 2009-11-19 Novo Nordisk A/S Long-acting y2 and/or y4 receptor agonists
WO2011033068A1 (en) * 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
TW201534616A (zh) * 2013-05-02 2015-09-16 Glaxosmithkline Ip Dev Ltd 治療性胜肽
MX369818B (es) * 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
AR104984A1 (es) 2015-06-12 2017-08-30 Novo Nordisk As Compuestos selectivos para pyy y sus usos
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法

Also Published As

Publication number Publication date
PH12021550964A1 (en) 2021-11-29
US20200140514A1 (en) 2020-05-07
US11820803B2 (en) 2023-11-21
AU2019371232B2 (en) 2022-07-14
US11155592B2 (en) 2021-10-26
JP7280949B2 (ja) 2023-05-24
TW202208410A (zh) 2022-03-01
MY197530A (en) 2023-06-21
TW202033544A (zh) 2020-09-16
CN112888705A (zh) 2021-06-01
KR20210071038A (ko) 2021-06-15
CL2021001073A1 (es) 2021-11-12
IL282177A (en) 2021-05-31
US20220025009A1 (en) 2022-01-27
BR112021006782A2 (pt) 2021-07-13
PE20211466A1 (es) 2021-08-05
AU2022231763A1 (en) 2022-10-06
AU2022231763B2 (en) 2024-05-09
MX2021004930A (es) 2021-06-08
DOP2021000072A (es) 2021-05-31
CO2021005514A2 (es) 2021-05-10
JP2023082013A (ja) 2023-06-13
WO2020092191A1 (en) 2020-05-07
EP3873924A1 (en) 2021-09-08
SG11202104161RA (en) 2021-05-28
TWI749381B (zh) 2021-12-11
CA3118002A1 (en) 2020-05-07
ECSP21030933A (es) 2021-05-31
AU2019371232A1 (en) 2021-05-20
JP2022506070A (ja) 2022-01-17

Similar Documents

Publication Publication Date Title
PH12021550964A1 (en) Protein tyrosine-tyrosine analogs and methods of using the same.
MX2022001136A (es) Analogos de relaxina y metodos para usarlos.
PH12020551742A1 (en) Gip derivatives and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2020057541A8 (en) Anti-ifnar1 antibodies for treating autoimmune diseases
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MY181181A (en) Fgf21 derivatives and uses thereof
WO2019087083A3 (en) Oral delivery of glp-1 peptide analogs
MX2020012273A (es) Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CR20200487A (es) Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estos
JOP20220071A1 (ar) سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
JOP20220110A1 (ar) ناهضات مستقبل npy2
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2021008941A (es) Moduladores gpr35.
EA202190923A1 (ru) Аналоги белка тирозин-тирозин и способы их применения
PH12021550839A1 (en) Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
AR116803A1 (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
AU2019253577A1 (en) Oxytocin compositions and methods of use
EA202191511A1 (ru) Составы на основе аналога пептида оксинтомодулина
CR20220046A (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1